Email this article Type 2 diabetes and cognitive functions in patients with chronic cerebrovascular diseases
- Authors: Tanashyan M.M.1, Surkova E.V.2, Antonova K.V.1, Lagoda O.V.1, Naminov A.V.1, Berdnikovich E.S.1, Fedin P.A.2, Titkova I.I.1
-
Affiliations:
- Research Center of Neurology
- Endocrinology Research Centre
- Issue: Vol 93, No 10 (2021)
- Pages: 1179-1185
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/86920
- DOI: https://doi.org/10.26442/00403660.2021.10.201108
- ID: 86920
Cite item
Full Text
Abstract
Background. Type 2 diabetes (Т2DM) both directly and indirectly impacts the development of morphological and functional changes of the central nervous system.
Aim. The study was to determine clinical and neurophysiological patterns of cognitive impairment (CI) in patients with chronic cerebrovascular diseases (CCD) and Т2DM.
Materials and methods. We examined 132 patients with CCD. First group included 58 patients without Т2DM aged 64.5 [58; 72], second group – 74 patients with CCD and Т2DM 63 [57; 70]. Clinical, neurological, neuropsychological, neurophysiological (cognitive evoked potentials (EP) and neurovisualisation (brain MRI) examination was carried out to all patients.
Results. Somatic and neurological characteristics of the patients were similar in both groups with the exception of more distinct metabolic changes in Т2DM patients. Neurovisualisation study of the brain MRI in Т2DM patients revealed more distinct changes in the form of white matter hyperintensity and subarachnoidal spaces enlargement. Neuropsychological examination in patients revealed the reduction of intellectual flexibility, constructive praxis disruption, optical spatial dysfunction and deteoration of delayed word recall. Significant disorders in the way of overall cognitive impairment, lobar dysfunction and impaired verbal associative productivity, proved by statistically lower amplitude and higher latency of P300 EP peak were noted in Т2DM patients. Correlation links were detected: for P300 amplitude and direct and inverse number listing test (r=0.366 and r=0.520; p=0.006 and p<0.001 respectively); P300 latency and HbA1c (r=0.32; р<0.05) in group 2 and glucose levels in both groups (r=0.30; p<0.05); inverse relationship of latency with control functions evaluation (r=-0.34; p=0.008).
Conclusion. CCD especially with Т2DM manifests with neurocognitive imbalance, including control functions disruption and are accompanied by neurophysiological and neurovisualistion changes.
Full Text
##article.viewOnOriginalSite##About the authors
Marine M. Tanashyan
Research Center of Neurology
Email: alexanaminov@mail.ru
ORCID iD: 0000-0002-5883-8119
чл.-кор. РАН, проф., зам. дир. по научной работе, зав. 1-м неврологическим отд-нием
Russian Federation, MoscowElena V. Surkova
Endocrinology Research Centre
Email: alexanaminov@mail.ru
ORCID iD: 0000-0002-3973-7638
д-р мед. наук, гл. науч. сотр., проф. каф. диабетологии и диетологии отд. прогнозирования и инноваций диабета
Russian Federation, MoscowKseniia V. Antonova
Research Center of Neurology
Email: alexanaminov@mail.ru
ORCID iD: 0000-0003-2373-2231
д-р мед. наук, ст. науч. сотр.
Russian Federation, MoscowOlga V. Lagoda
Research Center of Neurology
Email: alexanaminov@mail.ru
ORCID iD: 0000-0001-7562-4991
канд. мед. наук, ст. науч. сотр.
Russian Federation, MoscowAlexander V. Naminov
Research Center of Neurology
Author for correspondence.
Email: alexanaminov@mail.ru
ORCID iD: 0000-0003-3394-8976
аспирант 1-го неврологического отд-ния
Russian Federation, MoscowElena S. Berdnikovich
Research Center of Neurology
Email: alexanaminov@mail.ru
ORCID iD: 0000-0002-7608-2255
канд. мед. наук, рук. психолого-логопедической группы, ст. науч. сотр.
Russian Federation, MoscowPavel A. Fedin
Endocrinology Research Centre
Email: alexanaminov@mail.ru
ORCID iD: 0000-0001-9907-9393
канд. мед. наук, вед. научн. сотр.
Russian Federation, MoscowIrina I. Titkova
Research Center of Neurology
Email: alexanaminov@mail.ru
ORCID iD: 0000-0001-8936-5804
мед. психолог
Russian Federation, MoscowReferences
- Lin X, Xu Y, Pan X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep. 2020;10(1):14790. doi: 10.1038/s41598-020-71908-9
- Яхно Н.Н. Когнитивные расстройства в неврологической клинике. Неврологический журнал. 2006;11(Прил. 1):4-12 [Yakhno NN. Cognitive impairment in neurological pattern. Nevrologicheskii zhurnal. 2006;11(Pril. 1):4-12 (in Russian)]
- Medvidovic S, Titlic M, Maras-Simunic M. P300 evoked potential in patients with mild cognitive impairment. Acta Inform Med. 2013;21(2):89-92. doi: 10.5455/aim.2013.21.89-92
- De Salvo S, Lo Buono V, Bonanno L, et al. Role of visual P300 in cognitive assessment of subacute stroke patients: a longitudinal study. Int J Neurosci. 2020;130(7):722-6. doi: 10.1080/00207454.2019.1705808
- Miles WR. Psychologic tests applied to diabetic patients. Arch Intern Med (Chic). 1922;30(6):767-77. doi: 10.1001/archinte.1922.00110120086003
- Dejong R. The Nervous System Complications of Diabetes Mellitus, with Special Reference to Cerebrovascular Changes. J Nerv Ment Dis. 1950;111:181-206.
- Mijnhout GS, Scheltens P, Diamant M. et al. Diabetic encephalopathy: A concept in need of a definition. Diabetologia. 2006;49(6):1447-8. doi: 10.1007/s00125-006-0221-8
- Zilliox LA, Chadrasekaran K, Kwan JY, et al. Diabetes and Cognitive Impairment. Curr Diab Rep. 2016;16(9):87. doi: 10.1007/s11892-016-0775-x
- Davis DH, Creavin ST, Yip JL, et al. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. Cochrane Database Syst Rev. 2015;2015(10):CD010775. doi: 10.1002/14651858.CD010775.pub2
- Wardlaw JM, Smith EE, Biessels GJ, et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013;12(8):822-38. doi: 10.1016/S1474-4422(13)70124-8
- Fazekas F. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351-6. doi: 10.2214/ajr.149.2.351
- Танашян М.М., Лагода О.В., Антонова К.В., и др. Основные патогенетические механизмы развития сосудистой патологии мозга при атеросклерозе и метаболическом синдроме: поиск путей коррекции. Анналы клинической и экспериментальной неврологии. 2016;10(2):5-10. [Tanashyan MM, Lagoda OV, Antonova KV, et al. The main pathogenetic mechanisms of vascular cerebral pathology associated with atherosclerosis and metabolic syndrome: the search for correction approaches. Annaly klinicheskoi i eksperimental'noi nevrologii. 2016;10(2):5-10 (in Russian)].
- Biessels GJ, van der Heide LP, Kamal A, et al. Ageing and diabetes: implications for brain function. Eur J Pharmacol. 2002;441(1-2):1-14. doi: 10.1016/s0014-2999(02)01486-3
- Hardigan T, Ward R, Ergul A. Cerebrovascular complications of diabetes: focus on cognitive dysfunction. Clin Sci (Lond). 2016;130(20):1807-22. doi: 10.1042/CS20160397
- Srikanth V, Sinclair AJ, Hill-Briggs F, et al. Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities. Lancet Diabetes Endocrinol. 2020;8(6):535-45. doi: 10.1016/S2213-8587(20)30118-2
- Ganguli M, Beer JC, Zmuda JM, et al. Aging, Diabetes, Obesity, and Cognitive Decline: A Population-Based Study. J Am Geriatr Soc. 2020;68(5):991-8. doi: 10.1111/jgs.16321
- Бобров А.Е., Володина М.Н., Агамамедова И.Н., и др. Психические расстройства у больных сахарным диабетом 2-го типа. РМЖ. 2018;1(I):28-33 [Bobrov АЕ, Volodina MN, Agamamedova IN, et al. Mental disorders in type 2 diabetic patients. RMJ. 2018;1(I);28-33 (in Russian)].
- Дубинина И.И., Жаднов В.А., Янкина С.В., и др. Симптомы депрессии и тревоги у больных сахарным диабетом 2 типа и цереброваскулярной болезнью. Сахарный диабет. 2012;15(4):59-62 [Dubinina II, Zhadnov VA, Yankina SV, et al. Anxiety and depressive disorders in patients with diabetes mellitus type 2 and cerebrovascular disease. Sakharnyi diabet. 2012;15(4):59-62 (in Russian)]. doi: 10.14341/2072-0351-5539
- Kawada T. Sertraline treatment in depressive patients with type 2 diabetes. Prim Care Diabetes. 2019;13(4):384-5. doi: 10.1016/j.pcd.2018.12.009
Supplementary files
